Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nymox secures Italian deal for Alzheimer's test:

This article was originally published in Clinica

Executive Summary

Nymox Pharmaceutical, of Maywood, New Jersey, has entered into a distribution agreement with Padua-based Italian medical diagnostics company Alifax, to market and sell Nymox's AlzheimAlert product in Italy. Nymox's urine test, an aid in the diagnosis of Alzheimer's disease, is available through the company's CLIA-certified clinical reference laboratory in the US, although a PMA application was rejected by the FDA last year and a second application has been lodged (see Clinica 1136, p 18). A recent report by the World Health Organization for the European Union has identified Alzheimer's disease as a major healthcare priority for Europe. Worldwide estimates of the current number of people with the condition range from 15 to 20 million.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts